CSRxP
@RxPricing
CSRxP fosters a national dialogue focused on the pricing of new high-cost drug therapies and striking a balance between innovation and affordability.
976 Following 3.4K Followers
Despite the savings greater biosimilar competition can deliver, Big Pharma continues to game the system to block more affordable alternatives from reaching patients.
Lawmakers should build on recent bipartisan work to advance bipartisan, market-based solutions. More from @Axios:
Show more
Multiple studies have found Big Pharma’s price hikes have little to no connection to the cost of their development or improvements in drugs’ efficacy.
Get the facts on how the pharmaceutical industry continues to debunk its own rhetoric on innovation:
Show more
